Biologic Drug Report - News about biologics

A variety of other biological products, treating ailments ranging from asthma to osteoporosis to acute coronary syndrome and ischemic stroke, had total sales in 2005 estimated at more than $2 billion.

Here are some of the current uses for a variety of biologics.

Name	Company	Class	Use
Forteo	Eli Lilly	Recombinant human parathyroid hormone PTH (1-34)	Treatment for osteoporosis
Integrilin	Schering- Plough	Peptide	Treatment for acute coronary syndrome
Xolair	Genentech / Novartis	Recombinant humanized monoclonal antibody	Treatment for asthma
Pulmozyme	Genentech / Roche	Recombinant human protein	Treatment for cystic fibrosis
Activase / TNKase	Genentech / Roche	Recombinant human native or modified t-PA	Treatment for acute myocardial infarction, ischemic stroke, catheter clearance
BMP-2	Wyeth	Recombinant human bone morphogenic protein	Treatment for spinal fusion and long bone fusion
Xigris	Eli Lilly	Recombinant human activated protein C	Treatment for severe sepsis
Raptiva	Genentech / Serono	Recombinant humanized monoclonal antibody	Treatment for mild to moderate psoriasis
Thyrogen / Thyrotropin	Genzyme	Recombinant human thryoid stimulating hormone	Adjunct treatment for thyroid cancer
Amevive	Biogen IDEC	Recombinant human fusion protein of LFA-3 and Ig	Treatment for psoriasis
Zevalin	Biogen IDEC	IOD labeled monoclonal antibody	Treatment for non-Hodgkins lymphoma

Advertising Policy

Privacy Policy | Terms and Disclaimers | About the Biologic Drug Report

Contact Us

We subscribe to the HONcode principles of the HON Foundation.

This is an independent news site reporting on Biologic Drugs. Nothing on this site is intended as medical advice. The information provided here is for informational purposes only. Always consult a doctor or medical professional with questions you may have regarding a medical condition.

Last Updated: 01/14/2007